Skip to main content
Terug
SNPHF logo

Santen Pharmaceutical Co., Ltd.

Datakwaliteit: 100%
Overbought
SNPHF
OTC Healthcare Drug Manufacturers - General
€ 10,99
€ 0,00 (0,00%)
Marktkapitalisatie: 3,54B
Ook genoteerd als SNPHY OTC
Dagbereik
€ 10,99 € 10,99
52-Weeksbereik
€ 8,88 € 11,45
Volume
2.000
50D / 200D Gem.
€ 9,69 / € 10,54
Vorige Slotkoers
€ 10,99

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 12,2 3,7
Net Margin % 12,1 3,8
Rev Growth 5Y % 4,7 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 177,59
€ 161,40 – € 185,56
 390 B 1
FY2029 € 166,99
€ 151,77 – € 174,49
 370 B 1
FY2028 € 134,13
€ 121,91 – € 140,15
 310 B 1

Belangrijkste Punten

Revenue grew 4,71% annually over 5 years — modest growth
Earnings grew 36,09% over the past year
ROE of 12,24% — decent returns on equity
Debt/Equity of 0,12 — conservative balance sheet
Generating 54,27B in free cash flow
P/E of 0,10 — trading at a low valuation

Groei

Revenue Growth (5Y)
4,71%
Revenue (1Y)-0,65%
Earnings (1Y)36,09%
FCF Growth (3Y)107,87%

Kwaliteit

Return on Equity
12,24%
ROIC10,97%
Net Margin12,09%
Op. Margin15,63%

Veiligheid

Debt / Equity
0,12
Current Ratio2,58
Interest Coverage17,26

Waardering

P/E Ratio
0,10
P/B Ratio0,01
EV/EBITDA-1,18
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0,65% Revenue Growth (3Y) 3,69%
Earnings Growth (1Y) 36,09% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 4,71% Earnings Growth (5Y) 51,79%
Profitability
Revenue (TTM) 300,00B Net Income (TTM) 36,26B
ROE 12,24% ROA 8,86%
Gross Margin 57,01% Operating Margin 15,63%
Net Margin 12,09% Free Cash Flow (TTM) 54,27B
ROIC 10,97% FCF Growth (3Y) 107,87%
Safety
Debt / Equity 0,12 Current Ratio 2,58
Interest Coverage 17,26 Dividend Yield 0,02%
Valuation
P/E Ratio 0,10 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 0,35
EV/EBITDA -1,18 Dividend Yield 0,02%
Market Cap 3,54B Enterprise Value -55,23B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 300,00B 301,97B 279,04B 266,26B 249,61B
Net Income 36,26B 26,64B -14,95B 27,22B 6,83B
EPS (Diluted) 103,68 72,37 -38,58 67,97 17,06
Gross Profit 171,03B 178,71B 166,09B 156,59B 151,38B
Operating Income 46,88B 38,54B -3,09B 35,89B 37,80B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 409,28B 435,70B 421,18B 459,98B 402,35B
Total Liabilities 124,10B 130,33B 127,88B 123,13B 95,30B
Shareholders' Equity 286,24B 306,06B 293,98B 337,49B 307,59B
Total Debt 34,23B 35,16B 36,21B 32,93B 10,15B
Cash & Equivalents 93,00B 94,58B 57,90B 83,01B 62,89B
Current Assets 224,30B 236,14B 213,33B 229,43B 206,23B
Current Liabilities 86,84B 92,80B 89,50B 95,82B 78,55B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#292 of 827
50
Value Defensive Investing (Benjamin Graham)
#508 of 709
17

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026